Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Axogen, Inc., ICU Medical or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Axogen, Inc., ICU Medical and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Axogen, Inc., ICU Medical and Inc.

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company’s customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Latest Health Care Equipment & Supplies and Axogen, Inc., ICU Medical, Inc. Stock News

As of July 30, 2026, Axogen, Inc. had a $2.2 billion market capitalization, compared to the Health Care Equipment & Supplies median of $334.8 million. Axogen, Inc.’s stock is up 27.6% in 2026, up 5.7% in the previous five trading days and up 207.89% in the past year.

Currently, Axogen, Inc. does not have a price-earnings ratio. Axogen, Inc.’s trailing 12-month revenue is $238.1 million with a -13.4% net profit margin. Year-over-year quarterly sales growth most recently was 26.5%. Analysts expect adjusted earnings to reach $0.440 per share for the current fiscal year. Axogen, Inc. does not currently pay a dividend.

As of July 30, 2026, ICU Medical, Inc. had a $4.2 billion market cap, putting it in the 64th percentile of all stocks. ICU Medical, Inc.’s stock is up 18.6% in 2026, up 7.5% in the previous five trading days and up 32.77% in the past year.

Currently, ICU Medical, Inc.’s price-earnings ratio is 90.9. ICU Medical, Inc.’s trailing 12-month revenue is $2.2 billion with a 2.1% net profit margin. Year-over-year quarterly sales growth most recently was -12.3%. Analysts expect adjusted earnings to reach $8.165 per share for the current fiscal year. ICU Medical, Inc. does not currently pay a dividend.

How We Compare Axogen, Inc., ICU Medical and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Axogen, Inc., ICU Medical and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Axogen, Inc., ICU Medical and Inc. Stock Value Grades

Company	Ticker	Value
Axogen, Inc.	AXGN	F
ICU Medical, Inc.	ICUI	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Axogen, Inc. has a Value Score of 2, which is Ultra Expensive. ICU Medical, Inc. has a Value Score of 24, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Axogen, Inc., ICU Medical or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Axogen, Inc., ICU Medical or Inc. is the better investment when it comes to value.

Axogen, Inc., ICU Medical and Inc. Growth Grades

Company	Ticker	Growth
Axogen, Inc.	AXGN	C
ICU Medical, Inc.	ICUI	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Axogen, Inc. has a Growth Score of 48, which is Average. ICU Medical, Inc. has a Growth Score of 38, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Axogen, Inc., ICU Medical or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Axogen, Inc., ICU Medical or Inc. is the better investment when it comes to sustainable growth.

Axogen, Inc., ICU Medical and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Axogen, Inc.	AXGN	F
ICU Medical, Inc.	ICUI	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Axogen, Inc. has a Earnings Estimate Score of 20, which is Very Negative. ICU Medical, Inc. has a Earnings Estimate Score of 68, which is Positive.

The Earnings Estimate Revisions Grade Winner: ICU Medical, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, ICU Medical, Inc. has a better Earnings Estimate Revisions Grade than Axogen, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, ICU Medical, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Axogen, Inc., ICU Medical and Inc. Grades

In addition to Value, Estimate Revisions and Growth, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Axogen, Inc., ICU Medical and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Axogen, Inc., ICU Medical or Inc. Stock?

Overall, Axogen, Inc. stock has a Value Score of 2, Growth Score of 48 and Estimate Revisions Score of 20.

ICU Medical, Inc. stock has a Value Score of 24, Growth Score of 38 and Estimate Revisions Score of 68.

Comparing Axogen, Inc., ICU Medical and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.